SARS-CoV-2 Variant Under Investigation 202012/01 has more than twofold replicative advantage

Frederic Grabowski; Grzegorz Preibisch; Marek Kochańczyk; Tomasz Lipniacki

doi:10.1101/2020.12.28.20248906

Data Availability

All data used in this study are referenced. GISAID: www.gisaid.org; UK.GOV: https://coronavirus.data.gov.uk/details/cases

Comments

medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions and read our Comment Policy before commenting. The content of a comment is not endorsed by medRxiv.

Community Reviews

medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors.

Community reviews for this article:

There are no community reviews for this paper.

Automated Evaluations

Certain services provide automated analysis of preprints. Analyses invited by the authors are displayed at the top of this tab. Those done independently of authors are shown underneath . None of these analyses is endorsed by medRxiv.

Automated Evaluations:

There are no automated evaluations for this paper.

SARS-CoV-2 Variant Under Investigation 202012/01 has more than twofold replicative advantage

Data Availability

Subject Area

Citation Manager Formats

SARS-CoV-2 Variant Under Investigation 202012/01 has more than twofold replicative advantage

Data Availability

Subject Area

Follow this preprint